HDL function and mortality in end stage renal disease
HDL function and mortality in end stage renal disease
批准号:
9237202
负责人:
Hamid Moradi
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-01-01 至 2019-12-31
关键词:
AcidsAgeAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsApolipoprotein A-IAreaAtherosclerosisAwardCaliforniaCardiovascular DiseasesCardiovascular systemCaringCell Culture TechniquesCeramidesCessation of lifeChronic Kidney FailureClinicalClinical DataClinical ResearchCoronary ArteriosclerosisData CollectionDeficiency DiseasesDiabetes MellitusDialysis patientsDialysis procedureDisease susceptibilityEnd stage renal failureEndocannabinoidsEnvironmentEthnic OriginEvaluationFatty AcidsFoundationsFunctional disorderFutureGenderGeneral PopulationGoalsHealthcare SystemsHemodialysisHigh Density Lipoprotein CholesterolHigh Density LipoproteinsHigh PrevalenceHypertensionIn VitroInflammationInvestigationK-Series Research Career ProgramsKnowledgeLaboratoriesLegal patentLipidsLow Density Lipoprotein oxidationMaintenanceMalignant NeoplasmsMeasurementMeasuresMediator of activation proteinMentorsMentorshipMetabolismModelingNational Institute of Diabetes and Digestive and Kidney DiseasesOutcomeOxidative StressPathway interactionsPatientsPharmacologyPharmacology StudyPhenotypePlayPopulationPrevalencePreventionProductionPropertyProspective cohortPublic HealthRaceResearch PersonnelResourcesRiskRoleSamplingSerumSignal PathwayTechniquesTherapeuticTimeTrainingTraining ProgramsTranslational ResearchUnited StatesVeteransadjudicationamidaseatherogenesisbasecardiovascular disorder riskcardiovascular risk factorcareercohortdesignepidemiology studyexperienceexperimental studyhigh riskimprovedinhibitor/antagonistinnovationmortalitymultidisciplinarynew therapeutic targetnovelpatient populationprognosticprospectivepublic health relevancereverse cholesterol transporttargeted treatmenttool
中文摘要
描述(由申请人提供):
大约9%的美国人口患有慢性肾脏疾病,但考虑到糖尿病和高血压(CKD的潜在原因)在这一患者群体中的高患病率,退伍军人中的这一患病率甚至更高。在这个令人震惊的数字中,大约有450,000名患者患有终末期肾病(ESRD),需要维持透析。到2020年,ESRD患者的数量预计将增加到70万人。接受透析的患者的五年存活率约为35%,这一比率比许多癌症都要差。这些死亡中有一半可归因于心血管疾病(CVD)。因此,研究旨在发现新的途径/分子,以识别心血管疾病的高危患者是至关重要的。此外,可以探索这些途径来确定潜在的治疗靶点。鉴于高密度脂蛋白在预防和逆转心血管疾病中的关键作用,旨在评估和改善终末期肾病患者高密度脂蛋白功能的研究具有相当大的临床和治疗价值。
英文摘要
DESCRIPTION (provided by applicant):
Approximately 9% of the United States population have chronic kidney disease, although, this prevalence is even higher in Veterans given the high prevalence of diabetes and hypertension (underlying causes of CKD) in this patient population. Out of this staggering number, approximately 450,000 patients have end stage renal disease (ESRD) requiring maintenance dialysis. The number of patients with ESRD is expected to increase to 700,000 by 2020. Five year survival for patients on dialysis is about 35%, a rate worse than many cancers. Half of these deaths are attributed to cardiovascular disease (CVD). Therefore, investigations aimed at discovering novel pathways/molecules that can identify patients at high risk for CVD are of vital importance. Furthermore, these pathways can be explored to identify potential targets for therapy. Given the critical role HDL plays in prevention and reversal of CVD, studies aimed at evaluating and improving HDL function in ESRD patients are of considerable clinical and therapeutic value.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HDL function and mortality in end stage renal disease
-
批准号:10205993
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Hamid Moradi
-
依托单位:
Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
-
批准号:8122373
-
项目类别:
-
资助金额:$6.3万
-
财政年份:2009
-
负责人:Hamid Moradi
-
依托单位:
Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
-
批准号:7673186
-
项目类别:
-
资助金额:$6.1万
-
财政年份:2009
-
负责人:Hamid Moradi
-
依托单位:
Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
-
批准号:8039951
-
项目类别:
-
资助金额:$6.17万
-
财政年份:2009
-
负责人:Hamid Moradi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: